Septerna (NASDAQ:SEPN) Now Covered by Stifel Nicolaus

Stifel Nicolaus began coverage on shares of Septerna (NASDAQ:SEPN) in a report published on Friday morning, Marketbeat reports. The brokerage issued a buy rating and a $43.00 price objective on the stock.

SEPN has been the topic of several other reports. Cantor Fitzgerald reissued an “overweight” rating and set a $60.00 target price on shares of Septerna in a research note on Tuesday, March 10th. Truist Financial boosted their target price on Septerna from $34.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a research note on Tuesday, April 21st. HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Septerna in a research note on Tuesday, April 14th. Finally, Zacks Research raised Septerna from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $43.13.

Septerna Price Performance

Septerna stock traded down $0.15 during trading hours on Friday, reaching $23.61. The company had a trading volume of 201,575 shares, compared to its average volume of 341,018. The company has a 50-day moving average price of $25.77 and a 200 day moving average price of $25.34. The firm has a market cap of $1.06 billion, a price-to-earnings ratio of -21.27 and a beta of 2.22. Septerna has a 12-month low of $6.41 and a 12-month high of $32.63.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings results on Monday, March 9th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.01). Septerna had a negative return on equity of 15.85% and a negative net margin of 106.37%. As a group, research analysts expect that Septerna will post -1.57 earnings per share for the current year.

Insider Activity at Septerna

In related news, COO Elizabeth Bhatt sold 4,000 shares of Septerna stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $24.34, for a total transaction of $97,360.00. Following the sale, the chief operating officer directly owned 174,209 shares in the company, valued at $4,240,247.06. The trade was a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Samira Shaikhly sold 70,453 shares of Septerna stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $28.10, for a total value of $1,979,729.30. Following the sale, the insider owned 793 shares in the company, valued at $22,283.30. This represents a 98.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 78,453 shares of company stock worth $2,192,969 over the last 90 days. 4.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Septerna

Several hedge funds have recently made changes to their positions in the company. Deutsche Bank AG boosted its position in shares of Septerna by 5.3% during the fourth quarter. Deutsche Bank AG now owns 14,879 shares of the company’s stock valued at $415,000 after purchasing an additional 744 shares in the last quarter. Global Retirement Partners LLC bought a new stake in Septerna in the fourth quarter worth $35,000. Covestor Ltd boosted its holdings in Septerna by 55.8% in the third quarter. Covestor Ltd now owns 3,620 shares of the company’s stock worth $68,000 after acquiring an additional 1,296 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Septerna by 15.0% in the second quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock worth $107,000 after acquiring an additional 1,315 shares in the last quarter. Finally, PharVision Advisers LLC boosted its holdings in Septerna by 17.5% in the third quarter. PharVision Advisers LLC now owns 11,932 shares of the company’s stock worth $224,000 after acquiring an additional 1,780 shares in the last quarter.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.